Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Buy
54
NVS Quote, Financials, Valuation and Earnings
Last price:
$138.91
Seasonality move
:
-1.21%
Day range:
$138.53 - $139.48
52-week range:
$96.91 - $140.18
Dividend yield:
2.88%
P/E ratio:
18.94x
P/S ratio:
5.03x
P/B ratio:
6.01x
Volume:
647K
Avg. volume:
1.7M
1-year change:
41.21%
Market cap:
$266.5B
Revenue:
$50.3B
EPS (TTM):
$7.33
Analysts' Opinion
-
Consensus RatingNovartis AG has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 6 Hold ratings, and 2 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $134.88, Novartis AG has an estimated downside of -2.88% from its current price of $138.88.
-
Price Target UpsideAccording to analysts, the highest upside price target is $156.00 representing -100% upside increase from its current price of $138.88.
Fair Value
-
According to the consensus of 9 analysts, Novartis AG has -2.88% downside to fair value with a price target of $134.88 per share.
NVS vs. S&P 500
-
Over the past 5 trading days, Novartis AG has overperformed the S&P 500 by 1.4% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Novartis AG does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Novartis AG has grown year-over-year revenues for 9 quarters straight. In the most recent quarter Novartis AG reported revenues of $13.9B.
Earnings Growth
-
Novartis AG has grown year-over-year earnings for 3 quarters straight. In the most recent quarter Novartis AG reported earnings per share of $2.02.
Enterprise value:
289.2B
EV / Invested capital:
3.77x
Price / LTM sales:
5.03x
EV / EBIT:
16.73x
EV / Revenue:
5.31x
PEG ratio (5yr expected):
0.09x
EV / Free cash flow:
16.86x
Price / Operating cash flow:
15.96x
Enterprise value / EBITDA:
12.86x
Gross Profit (TTM):
$41B
Return On Assets:
13.81%
Net Income Margin (TTM):
26.48%
Return On Equity:
33.87%
Return On Invested Capital:
19.37%
Operating Margin:
30.24%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $44.7B | $48.6B | $54.4B | $12.8B | $13.9B | |
| Gross Profit | $32.1B | $35.9B | $41B | $9.5B | $10.3B | |
| Operating Income | $12.5B | $14.4B | $17.3B | $4.1B | $4.2B | |
| EBITDA | $21B | $20.4B | $22.5B | $6B | $5.5B | |
| Diluted EPS | $3.72 | $8.57 | $7.33 | $1.57 | $2.02 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $26.3B | $37B | $45.7B | $31.3B | $28.2B | |
| Total Assets | $121.2B | $118.5B | $112.7B | $103.5B | $107.3B | |
| Current Liabilities | $29.9B | $28.2B | $48.4B | $28.1B | $32B | |
| Total Liabilities | $64.3B | $57.6B | $74.5B | $60.1B | $62.5B | |
| Total Equity | $56.9B | $60.9B | $38.2B | $43.4B | $44.8B | |
| Total Debt | $25B | $21.5B | $19.7B | $25.6B | $24.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $16.1B | $16B | $21.2B | $6.3B | $6.6B | |
| Cash From Investing | $5.3B | -$5.6B | -$5.8B | -$374M | -$858.2M | |
| Cash From Financing | -$17.7B | -$9.4B | -$19.7B | -$382M | -$2.8B | |
| Free Cash Flow | $13.6B | $12.5B | $17.1B | $5.5B | $5.7B | |
NVS
Sector
Market Cap
$266.5B
$28.1M
Price % of 52-Week High
99.08%
51.39%
Dividend Yield
2.88%
0%
Shareholder Yield
7.14%
-1.49%
1-Year Price Total Return
41.21%
-17.13%
Beta (5-Year)
0.525
0.518
Dividend yield:
2.88%
Annualized payout:
$3.74
Payout ratio:
-57.72%
Growth streak:
5 years
Technicals
8-day SMA
Buy
Level
$136.43
200-day SMA
Buy
Level
$120.89
Bollinger Bands (100)
Buy
Level
123 - 132.72
Chaikin Money Flow
Buy
Level
339.4M
20-day SMA
Buy
Level
$133.46
Relative Strength Index (RSI14)
Buy
Level
70.92
ADX Line
Buy
Level
22.18
Williams %R
Sell
Level
-12.7023
50-day SMA
Buy
Level
$130.29
MACD (12, 26)
Buy
Level
2.31
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
233.1M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.4106)
Buy
CA Score
(Annual)
Level (0.0643)
Buy
Beneish M-Score
(Annual)
Level (-2.6656)
Buy
Momentum Score
Level (6)
Buy
Ohlson Score
Level (-1.6481)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Stock Forecast FAQ
In the current month, NVS has received 1 Buy ratings 6 Hold ratings, and 2 Sell ratings. The NVS average analyst price target in the past 3 months is $134.88.
-
Where Will Novartis AG Stock Be In 1 Year?
According to analysts, the consensus estimate is that Novartis AG share price will drop to $134.88 per share over the next 12 months.
-
What Do Analysts Say About Novartis AG?
Analysts are divided on their view about Novartis AG share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that Novartis AG is a Buy and believe this share price will rise from its current level to $156.00.
-
What Is Novartis AG's Price Target?
The price target for Novartis AG over the next 1-year time period is forecast to be $134.88 according to 9 Wall Street analysts, 1 of them rates the stock a Buy, 2 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is NVS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Novartis AG is a Hold. 6 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of NVS?
You can purchase shares of Novartis AG via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Novartis AG shares.
-
What Is The Novartis AG Share Price Today?
Novartis AG was last trading at $138.91 per share. This represents the most recent stock quote for Novartis AG. Yesterday, Novartis AG closed at $138.88 per share.
-
How To Buy Novartis AG Stock Online?
In order to purchase Novartis AG stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get NVS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NVS
Sector
P/E ratio
18.94x
23.89x
PEG ratio
0.09x
-0.01x
P/B ratio
6.01x
1.81x
Price / LTM sales
5.03x
1.59x
Growth Metrics
NVS
Sector
Revenue growth
8.21%
4.62%
Earnings growth
28.39%
11.06%
Revenue (5-year growth)
1.15%
6.5%
Earnings forecast
$2.31
-$0.21
Profitability
NVS
Sector
Profitability FY 2024
$37.5B
$3.6M
Return on invested capital
19.37%
-31.84%
Return on assets
13.81%
-27.96%
Return on equity
33.87%
-37.63%
Earnings Date
Last Earnings Date
Oct
28
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Jan
27
Balance Sheet
NVS
Sector
Total cash
$9.8B
$26.4M
Short term investments
$1.9B
$25.7M
Total assets
$106.8B
$76.9M
Long term debt
$24.5B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
85
HUT alert for Dec 25
Hut 8 Corp. [HUT] is up 0.65% over the past day.
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
63
GPCR alert for Dec 25
Structure Therapeutics, Inc. [GPCR] is down 2.36% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
